Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Povilaĭtite P.E.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

Petrov A.V.

State Research Institute of Highly Pure Biopreparations, Federal Biomedical Agency, St. Petersburg, Russia

Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer

Authors:

Pavlenko I.A., Povilaĭtite P.E., Gorelik M.Z., Petrov A.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2012;74(5): 36‑40

Read: 2858 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pavlenko IA, Povilaĭtite PE, Gorelik MZ, Petrov AV. Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer. Russian Journal of Archive of Pathology. 2012;74(5):36‑40. (In Russ.)

Подписка 2025-2 (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer. Russian Journal of Archive of Pathology. 2024;(4):23-30

Indocyanine green is an integral part of breast reconstructive surgery using perforator flaps. Pirogov Russian Journal of Surgery. 2024;(8):34-40

Hypoalbuminemia as an independent predictor of complications, critical illness and premature death. Russian Journal of Anesthesiology and Reanimatology. 2024;(4):83-89

Leading trends in breast cancer incidence in the Republic of Crimea. P.A. Herzen Journal of Oncology. 2024;(4):42-47

Influence of cardiorespiratory training program on the intercellular adhesion molecule level in patients with postmastectomy syndrome. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):45-51

Prediction of papillary thyroid cancer recurrence according to preoperative data. Pirogov Russian Journal of Surgery. 2024;(9):76-85

Prognostic value of right ventricular dysfunction in patients with left ventricular non-compaction cardiomyopathy. Russian Cardiology Bulletin. 2024;(3):62-70

Prognostic scale for early detection of various postoperative complications after thoracic aortic surgery: post-hoc analysis of biomarkers. Pirogov Russian Journal of Surgery. 2024;(10):38-48

Diagnostic value of fluorescence lymphography for sentinel lymph node biopsy in breast cancer. Summary experience of several specialized centers. Pirogov Russian Journal of Surgery. 2024;(10):49-61

PET/CT with 11C-methionine as a predictor of disease-free survival in patients with IDH1 wild type diffuse glioma. Burdenko's Journal of Neurosurgery. 2024;(5):6-13

It is well known that breast cancers (BC) are divided into 4 molecular genetic subgroups (luminal A, luminal B, HER2/neu-positive, and triple-negative (TNBC). The purpose of the investigation was to comparatively estimate the pattern of expression of Bcl-2, known as a good prognostic marker of BC, in different molecular genetic subgroups and to study the correlation of this protein with proliferative activity index and genetic aberrations on chromosome 17. The investigation covered 290 samples of invasive ductal BC. Bcl-2 expression was identified in 14% of HER2/neu-positive and TNBC cases while 77% of luminal B tumors and 100% of luminal A ones expressed Bcl-2. Loss of Bcl-2 expression correlated with clinically more aggressive BCs having a high proliferative activity and amplification of HER2/neu and chromosome 17 centromere. This may suggest the poor prognosis of luminal B, HER2/neu-positive and TNBC with no Bcl-2 expression and calls for further investigations on larger samples.

Keywords:

breast cancer

Bcl-2

proliferation

prognosi

Authors:

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Povilaĭtite P.E.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

Petrov A.V.

State Research Institute of Highly Pure Biopreparations, Federal Biomedical Agency, St. Petersburg, Russia

List of references:

Zavalishina L.E., Andreeva Yu.Yu., Ryazantseva A.A., Frank G.A. Issledovanie HER2/neu-statusa raka molochnoi zhelezy. Metodicheskie aspekty. Arkhiv patologii. 2011; 1: 51-4.
Raikhlin N.T., Raikhlin A.N. Regulyatsiya apoptoza v fiziologicheskikh usloviyakh i v opukholyakh. Voprosy onkologii. 2002; 48 (2): 159-71.
Abdel-Fatah T., Dickinson P., Moseley P. Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. J. Clin. Oncol. 2011; 29 (suppl.): abstr 1024.
Callagy G., Pharoah P., Pinder S., Hsu F., Nielsen T., Ragaz J. et al. Bcl-2 Is a prognostic marker in breast cancer independently of the nottingham prognostic index. Clin. Cancer. Res. 2006; 12 (8): 2468-75.
Cheang M., Chia S., Voduc D., Gao D., Leung S., Snider J. et al. Ki-67 index, HER2/neu status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 2009; 101 (10): 736-50.
Crawford A., Nahta R. Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr. Pharm. Person. Med. 2011; 9 (3): 184-90.
Dawson S., Makretsov N., Blows F., Driver K., Provenzano E., Le Quesne J. et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br. J. Cancer. 2010; 103 (5): 668-75.
Frenzel A., Grespi F., Chmelewskij W., Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009; 14 (4): 584-96.
Goldhirsch A., Wood W., Coates A., Gelber R., ThÜrlimann B., Senn H. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011; 22 (8): 1736-47.
Kallel-Bayoudh I., Hassen H., Khabir A., Boujelbene N., Daoud J., Frikha M. et al. Bcl-2 expression and triple negative profile in breast carcinoma. Med. Oncol. 2011; 28 (suppl. 1): 55-61.
Kumar T., Kari V., Choudhary B., Nambiar M., Akila T., Raghavan S. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J. Biol. Chem. 2010; 285 (42): 32657-70.
Laulier C., Barascu A., Guirouilh-Barbat J., Pennarun G., Le Chalony C., Chevalier F. et al. Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res. 2011; 71 (10): 3590-602.
Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L., Botta C., Pasini B. et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219 (1): 16-24.
Martinez-Arribas F., Alvarez T., Del Val G., Martín-Garabato E., Núñez-Villar M., Lucas R. et al. Bcl-2 expression in breast cancer: A comparative study at the mRNA and protein level. Anticancer Res. 2007; 27 (1A): 219-22.
Perou C., Sørlie T., Elsen M., van de Rijn M., Jeffrey S., Rees C. et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747-52.
Rossiter H., Beissert S., Mayer C., Schön M., Wienrich B., Tschachler E. et al. Targeted expression of bcl-2 to murine basal epidermal keratinocytes results in paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis. Cancer Res. 2001; 61 (9); 3619-26.
Vairo G., Soos T., Upton T., Zalvide J., DeCaprio J., Ewen M. et al. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol. Cell Biol. 2000; 20 (13): 4745-53.
Yeh I.T., Martin M.A., Robetorye R.S., Bolla A.R., McCaskill C., Shah R.K. et al. Clinical validation of an array CGH test for HER2/neu status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 2009; 22 (9): 1169-75.

Close metadata